Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/48832| Title: | Decision-maker perspectives on outcomes studied in leukaemia clinical trials : the response evaluation in leukaemia (REVALEU) study protocol |
| Authors: | Said, Dylan Borg, John-Joseph Attard Pizzuto, Maresca Serracino-Inglott, Anthony |
| Keywords: | Leukemia -- Treatment Technology assessment, Biomedical -- Evaluation Clinical trials -- Decision making |
| Issue Date: | 2019-05 |
| Publisher: | University of Malta. Department of Pharmacy |
| Citation: | Said, D., Borg, J. J., Attard Pizzuto, M., & Serracino-Inglott, A. (2019, May). Decision-maker perspectives on outcomes studied in leukaemia clinical trials: the response evaluation in leukaemia ((REVALEU) study protocol. Poster session presented at the Professional Society for Health Economics and Outcomes Research (ISPOR) 2019 conference, New Orleans, USA. |
| Abstract: | A poster presentation about decision-maker perspectives on outcomes studied in leukaemia clinical trials: the response evaluation in leukaemia (REVALEU) study protocol. Objectives: Evidence of efficacy for antineoplastic agents may be valued differently by regulatory and health technology assessment (HTA) bodies in the European Union (EU), impacting decision-making and access to innovative therapies. The aim was to develop a study protocol to identify core efficacy outcomes prioritised by EU decision-makers for clinical trials (CTs) investigating leukaemic disorders. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/48832 |
| Appears in Collections: | Scholarly Works - FacM&SPha |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Decision_maker_perspectives_on_outcomes_studied_in_leukaemia_clinical_trials_2019.pdf | 1.72 MB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.